Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials (original) (raw)

2008, European Journal of Cancer

AI-generated Abstract

This paper discusses the optimization of imatinib dosing for the treatment of gastrointestinal stromal tumors (GIST) based on findings from phase 3 clinical trials. GISTs are primarily resistant to conventional therapies, and imatinib has significantly improved patient outcomes since its introduction as a targeted therapy. The analysis of the phase 3 studies reveals that while the standard starting dose is 400 mg/d, higher doses, particularly 800 mg/d, were evaluated for efficacy and safety, demonstrating a potential for improved progression-free survival, particularly in patients with specific genetic mutations. The results underscore the importance of personalized treatment strategies in optimizing therapeutic outcomes for GIST patients.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact